🔎 Trials Near Me

Beranda › Gangguan Depresi Mayor › Arkansas

Uji klinis Gangguan Depresi Mayor di Arkansas

15 studi untuk Gangguan Depresi Mayor mencari peserta di lokasi di Arkansas.

Kota di Arkansas

Teks studi resmi (Bahasa Inggris)

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

  • SanRo Clinical Research Group LLC WCG Clinical Network, Bryant
Menerima pesertaFase 3
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07573176

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

  • SanRo Clinical Research Group LLC WCG Clinical Network, Bryant
Menerima pesertaFase 3
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06559306

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

  • Vanda Investigational Site, Little Rock
Menerima pesertaFase 3
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06830044

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

  • Pillar Clinical Research, Bentonville
  • SanRo Clinical Research Group, Bryant
Menerima pesertaFase 3
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07076407

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

  • Draig Clinical Site, Little Rock
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07610473

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

  • Draig Clinical Site, Bentonville
  • Draig Clinical Site, Little Rock
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT07300969

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  • Neurocrine Clinical Site, Bryant
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT06911112

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

  • Preferred Research Partners, Inc., Little Rock
Menerima pesertaFase 3
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT07592689

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

  • Woodland International Research Group, Little Rock
  • Woodland Research Northwest, Rogers
Menerima pesertaFase 3
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT06775379

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  • Neurocrine Clinical Site, Bryant
  • Neurocrine Clinical Site, Little Rock
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jul 2026 · NCT06966401

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

  • Preferred Research Partners /ID# 279206, Little Rock
  • Woodland International Research Group /ID# 277605, Little Rock
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 15 Jun 2026 · NCT07276997

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

  • Pillar Clinical Research, LLC, Little Rock
  • Preferred Research Partners, Inc., Little Rock
  • Woodland Research Northwest, Rogers
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 11 Mei 2026 · NCT06524830

Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  • Neurocrine Clinical Site, Little Rock
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Okt 2025 · NCT06786624

Study of ALTO-300 in MDD

  • Site 193, Rogers
Menerima pesertaFase 2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 24 Jul 2025 · NCT05922878

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.